Abstract
Objective
To determine if choice of drug and ease of administration affect persistence of therapy with Cholinesterase inhibitors (ChEIs) for treatment of dementia.
Methods
An observational administrative health database study was conducted in 5622 patients aged ≥65 years who received a new prescription for donepezil (DON), rivastigmine (RIV) or galantamine (GAL) from February to May 2006. Patients were followed for 1 year from initiation of therapy to determine percentage persistence and days of therapy. Once-daily galantamine extended release (GAL-ER) was compared with twice-daily galantamine immediate release (GAL-IR) to determine if ease of administration affected persistence. Previous treatment with ChEIs was also documented.
Results
One-year persistence rates were significantly different among the ChEIs: GAL-ER 54% (95% CI 51, 57), DON 46% (95% CI 43, 49) and RIV 40% (95% CI 37, 43). Average days of therapy were greater for GAL-ER (293) than for RIV (272), but there were no differences between DON (287) and GAL-ER or DON and RIV. One-year persistence was significantly greater for GAL-ER 54% (95% CI 48, 59) than for GAL-IR 44% (95% CI 39, 50), although there was no significant difference in days of therapy (293 vs 286, respectively). More patients currently treated with RIV (40.5%) or GAL-ER (32.3%) had received previous treatment with a different ChEI than with DON (21.9%).
Conclusion
Among possible factors affecting persistence of ChEI therapy for dementia, choice of drug, ease of administration and previous treatment appear to be important.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899–913
Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf 2004; 3: 425–40
Hogan DB, Bailey P, Carswell A, et al. Management of mild to moderate Alzheimer’s disease and dementia. Alzheimers Dement 2007; 3: 355–84
Herrmann N, Gauthier S, Lysy P. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimers Dement 2007; 3: 385–97
Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231–51
Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer’s disease. Drugs Aging 2005; 22: 695–707
Dybicz SB, Keohane DJ, Erwin WG, et al. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006; 4: 154–60
Sicras-Mainar A, Vergara J, Leon-Colombo T, et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer’s disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol 2006; 43: 449–53
Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55: 1517–23
Seltzer B. Is long-term treatment of Alzheimer’s disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24: 881–90
Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol Sci 2005; 26: 104–11
AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD 2000): randomised double-blind trial. Lancet 2004; 363: 2105–15
Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3: 39–49
Acknowledgements
This study was funded by Janssen-Ortho Inc., who paid for the data acquisition and statistical analysis. Nathan Herrmann has received honoraria, consultation fees and/or research support from Janssen-Ortho Inc., Pfizer Canada Inc., Novartis Pharmaceuticals Canada Inc. and Lundbeck. William Dalziel has received honoraria and consultation fees from Janssen-Ortho Inc., Pfizer Canada Inc. and Novartis Pharmaceuticals Canada Inc. Carin Binder and Steve Smyth are employees of Janssen-Ortho Inc. Fernando Camacho is a consultant with Damos Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herrmann, N., Binder, C., Dalziel, W. et al. Persistence with Cholinesterase Inhibitor Therapy for Dementia. Drugs Aging 26, 403–407 (2009). https://doi.org/10.2165/00002512-200926050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200926050-00004